SLGL News and Press, Sol-Gel Technologies Ltd. From 05/13/22

Sol-Gel Technologies press release (NASDAQ:SLGL): Q1 GAAP EPS of -$0.18 beats by $0.11. As of March 31, 2022, Sol-Gel had $30.2 million in cash, cash equivalents and deposits, and $6.1 million in marketable securities for a total balance of $36.3 million. For further details see: Sol-Ge...

FDA approval for EPSOLAY ® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year ; EPSOLAY is patent protected until 2040 Partner Galderma to launch two products ...

The Food and Drug Administration (FDA) approved Sol-Gel Technologies (NASDAQ:SLGL) Epsolay, a proprietary cream formulation of benzoyl peroxide 5%, to treat inflammatory lesions of rosacea in adults. The company said the benzoyl peroxide in Epsolay is encapsulated within silica-based patented...

EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma set to commercialize EPSOLAY in the U.S. under exclusive license ...

TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acne Sol-Gel’s U.S. commercialization partner, Galderma, launched TWYNEO ® in the U.S. at the Annual Meeting of the American Academy of Dermatology, March 25-29, 2022 ...

Galderma launched TWYNEO ® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022. 2021 revenue of $31.3 million Sol-Gel to receive $21.5 million over 24 months in ex...

NESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that its U.S...

NESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the...

FDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14 th , 2022 NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatolo...

Sol-Gel Technologies (NASDAQ:SLGL): Q3 GAAP EPS of $0.05 beats by $0.12. Revenue of $8.83M (+316.5% Y/Y) beats by $1.21M. Press Release For further details see: Sol-Gel Technologies EPS beats by $0.12, beats on revenue